Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • PROCEPT BioRobotics' Capital Expenditures rose 106585.37% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 2736.4%. This contributed to the annual value of $4.4 million for FY2024, which is 8250.81% down from last year.
  • Per PROCEPT BioRobotics' latest filing, its Capital Expenditures stood at $2.9 million for Q3 2025, which was up 106585.37% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, PROCEPT BioRobotics' Capital Expenditures ranged from a high of $8.7 million in Q4 2023 and a low of $26000.0 during Q2 2021
  • For the 5-year period, PROCEPT BioRobotics' Capital Expenditures averaged around $2.2 million, with its median value being $1.2 million (2022).
  • In the last 5 years, PROCEPT BioRobotics' Capital Expenditures skyrocketed by 358888.89% in 2021 and then plummeted by 9574.39% in 2024.
  • PROCEPT BioRobotics' Capital Expenditures (Quarter) stood at $332000.0 in 2021, then skyrocketed by 429.22% to $1.8 million in 2022, then skyrocketed by 396.02% to $8.7 million in 2023, then crashed by 86.53% to $1.2 million in 2024, then soared by 144.29% to $2.9 million in 2025.
  • Its Capital Expenditures stands at $2.9 million for Q3 2025, versus $2.8 million for Q2 2025 and $1.8 million for Q1 2025.